血必净注射液治疗重症急性胰腺炎的Meta分析

目的评价血必净注射液对重症急性胰腺炎（SAP）患者的影响,从而了解血必净用于辅助治疗重症急性胰腺炎的临床疗效。方法选择符合纳入标准的随机或临床对照试验（CRT、CCT）文献,对数据进行Meta分析。结果5项研究纳入421例患者,Meta分析显示,血必净＋乌司他丁＋基础治疗组与乌司他丁＋基础治疗组比较,腹痛缓解时间（WMD=-1.86,95%CI：-2.27～-1.45,P=0.00001）、血淀粉酶恢复正常时间（WMD=-1.80,95%CI：-2.68～-0.93,P〈0.0001）、尿淀粉酶恢复正常时间（WMD=-1.96,95%CI：-2.42～-1.50,P〈0.00001）、白细胞计数恢复正常时间（WMD=-2.49,95%CI：-3.56～-1.41,P〈0.00001）以及总有效率（RR=1.16,95%CI：1.07～1.25,P=0.0002）的差异有统计学意义。结论应用血必净的治疗组能明显缩短重症急性胰腺炎患者腹痛缓解时间、血（尿）淀粉酶以及白细胞计数恢复正常时间,且治疗组的总有效率明显高于对照组。

Meta-Analysis of Xuebijing Treating Severe Acute Pancreatitis

Objective To evaluate the efficacy of Xuebijing injection for the treatment of severe acute pancreatitis. Methods Literatures of RCT（randomized controlled trial）or CCT（clinical controlled trial）were selected to Meta-analysis. Results Five randomized clinical trials with 421 patients were included.Meta-analysis showed that the abdominal pain time（WMD=-1.86,95%CI：-2.27 ～-1.45,P=0.00001） 、 restoration time of blood and urine amylase（WMD=-1.80,95% CI：-2.68～-0.93,P〈0.0001）、（WMD=-1.96,95% CI：-2.42～-1.50,P〈0.00001）、restoration time of white blood cell（WMD=-2.49,95% CI：-3.56～-1.41,P0.00001）and total efficiency（RR=1.16,95% CI：1.07～1.25,P=0.0002）of treatment group（Xuebijing＋Ulinastatin＋ based treatment）and the control group（Ulinastatin＋based treatment） the difference were statistically significant.Conclusion Current results indicated that the application of Xuebijing injection for the treatment of severe acute pancreatitis provided a shorter length of abdominal pain time、restoration time of blood（urine）amylase and white blood cell, and a higher total efficiency.